Opioid over/misuse is an enormous problem that practitioners and payers are working hard to address. To that end, Insight Diagnostics has just introduced a new, low cost, lab test that significantly improves the diagnostic capabilities of physicians treating patients who are being prescribed opioids. Insight has combined two widely used and often expensive lab tests Read More …

Opioid over/misuse is an enormous problem that practitioners and payers are working hard to address. To that end, Insight Diagnostics has just introduced a new, low cost, lab test that significantly improves the diagnostic capabilities of physicians treating patients who are being prescribed opioids. Insight has combined two widely used and often expensive lab tests Read More …

What do you think?  Should HHS and Medicare expand coverage for genetic tests?     http://www.natlawreview.com/article/hhs-and-medicare-asked-to-expand-coverage-genetic-tests

What’s the next big thing coming for healthcare? Results from the New England Journal of Medicine (NEJM) Catalyst Insights Survey on Care Redesign suggest that genomics and patient-generated data critical for precision medicine could surge in importance over the next five years. Savvy investors could profit from this increased demand for precision medicine data by buying Read More …

February 28, 2017 by Don Rule You’ve seen the alarming statistics: there are an estimated 100,000 deaths[i] and upwards of two million serious adverse drug reactions (ADRs) in the United States each year related to prescription drug use, costing the healthcare industry in excess of $136 billion annually according to the Food and Drug Administration. Read More …